Ronil A. Patel - 01 Dec 2023 Form 4 Insider Report for Ocuphire Pharma, Inc. (IRD)

Reporting relationship: Chief Business Officer
Issuer ticker: IRD
Reported as of: 01 Dec 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Dec 2023, 16:30:39 UTC
Prior SEC filing: 26 Apr 2023
Next SEC filing: 12 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Stephanie Swan, by Power of Attorney

Key filing fact

Ronil A. Patel filed Form 4 for Ocuphire Pharma, Inc. (IRD) on 05 Dec 2023.

Key facts

This page summarizes Ronil A. Patel's Form 4 filing for Ocuphire Pharma, Inc. (IRD).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Dec 2023, 16:30.

Change

Previous filing in this sequence was filed on 26 Apr 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OCUP transaction

Common Stock

Award

Transaction value: $0
Shares: +49,692
Change %: +117%
Price: $0.000000
Shares after: 91,996
Date: 01 Dec 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OCUP transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +74,538
Change %
Price: $0.000000
Shares after: 74,538
Date: 01 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 74,538
Exercise price: $2.99
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a grant of restricted stock units which vest with respect to 25% on the six month anniversary of the grant date, with the remaining shares vesting in equal installments every six months thereafter over the two years following the grant date, subject to continuing service.

Footnote F2

The option will vest with respect to 25% on the six month anniversary of the grant date, with the remaining shares vesting in equal installments every six months thereafter over the two years following the grant date, subject to continuing service.